Regulatory Reliance Behind The Success Of African COVID-19 Vaccine Approvals
Executive Summary
Regulatory reliance and work-sharing are becoming increasingly popular as a way of avoiding duplication and speeding up drug and vaccine assessments, but while there are many benefits, regulators should also be aware of some potential pitfalls, delegates at the TOPRA annual symposium heard this week.
You may also be interested in...
EU Joint Regulatory Assessment Project Bears Fruit In COVID-19
The European Medicines Agency has reported progress with a collaborative project that involves other regulators in its assessments of COVID-19 products, and with the EU Medicines for All initiative for evaluating products for non-EU markets.
Lean On Me: WHO Offers Practical Advice On Regulatory Reliance
A new draft document by the World Health Organization explains how regulatory authorities can leverage the work done by others to gain efficiencies and avoid duplication.
Swiss Finally Beat EMA On New Drug Approval Times
More rolling reviews, a reduction in review rounds, and a rise in applications through two international regulatory collaboration initiatives were among the factors behind a reduction in new drug authorization times in Switzerland last year. However, “submission gaps” versus other regulators remain a problem.